SAB Biotherapeutics (NASDAQ:SABS) Upgraded at Wall Street Zen

SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at Wall Street Zen to a “sell” rating in a report released on Saturday.

Other research analysts have also issued research reports about the stock. HC Wainwright dropped their price target on shares of SAB Biotherapeutics from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Tuesday, July 22nd. Leerink Partnrs upgraded SAB Biotherapeutics to a “strong-buy” rating in a research report on Wednesday. Chardan Capital reissued a “buy” rating and set a $12.00 price objective on shares of SAB Biotherapeutics in a report on Friday. Finally, Leerink Partners began coverage on shares of SAB Biotherapeutics in a report on Wednesday. They issued an “outperform” rating and a $7.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating and four have issued a Buy rating to the stock. Based on data from MarketBeat, SAB Biotherapeutics has a consensus rating of “Buy” and an average price target of $9.75.

SAB Biotherapeutics Stock Performance

Shares of NASDAQ SABS opened at $2.47 on Friday. The business’s 50-day simple moving average is $2.29 and its 200-day simple moving average is $1.89. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.87 and a current ratio of 0.87. SAB Biotherapeutics has a 52 week low of $1.00 and a 52 week high of $6.60. The firm has a market cap of $25.71 million, a price-to-earnings ratio of -0.62 and a beta of 0.54.

SAB Biotherapeutics (NASDAQ:SABS) last released its earnings results on Thursday, August 7th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.27). As a group, equities research analysts expect that SAB Biotherapeutics will post -3.69 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SAB Biotherapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. HB Wealth Management LLC increased its position in shares of SAB Biotherapeutics by 10.9% in the 1st quarter. HB Wealth Management LLC now owns 263,200 shares of the company’s stock valued at $358,000 after buying an additional 25,800 shares in the last quarter. Silver Oak Securities Incorporated acquired a new position in SAB Biotherapeutics in the first quarter valued at about $30,000. Finally, Northern Trust Corp bought a new stake in shares of SAB Biotherapeutics in the fourth quarter worth about $43,000. 7.82% of the stock is owned by institutional investors.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.